Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial 在既往使用胰岛素治疗血糖未得到控制的日本2型糖尿病受试者中比较德谷胰岛素/门冬胰岛素与每日2次双相门冬胰岛素30:泛亚达标治疗3期试验亚组分析
详细信息 查看全文
- 作者：Shinji Taneda ; Jacob Hyllested-Winge ; Mari-Anne Gall ; Shizuka Kaneko and Koichi Hirao
- 刊名：Journal of Diabetes
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：9
- 期：3
- 页码：243-247
- 全文大小：3605K
- ISSN：1753-0407
文摘
The present study was a subgroup analysis of a Pan-Asian Phase 3 open-label randomized treat-to-target trial evaluating insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) in Japanese subjects with type 2 diabetes inadequately controlled on insulin.